Andrea Sterman Heimann

Dr. Andrea Sterman Heimann

Proteimax Biotechnology Israel LTD, Pardés H̱anna Karkur, Haifa, Israel
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2019 in Biomolecules
Verified
Journal Article
Open access
PDF file
CAChristiane B. de Araujo
Christiane B. de Araujo
AHAndrea Sterman Heimann
Andrea Sterman Heimann
RRRicardo A. Remer
Ricardo A. Remer
LRLilian C. Russo
Lilian C. Russo
ACAlison Colquhoun
Alison Colquhoun
EFEmer Ferro
Emer Ferro
Intracellular peptides are produced by proteasomes following degradation of nuclear, cytosolic, and mitochondrial proteins, and can be further processed by additional peptidases generating a larger pool of peptides within cells. Thousands of intracellular peptides have been sequenced in plants, yeast, zebrafish, rodents, and in human cells and tissues. Relative levels of intracellular peptides undergo changes in human diseases and also when cells are stimulated, corroborating their biological function. However, only a few intracellular peptides have been pharmacologically characterized and their biological significance and mechanism of action remains elusive. Here, some historical and general aspects on intracellular peptides’ biology and pharmacology are presented. Hemopressin and Pep19 are examples of intracellular peptides pharmacologically characterized as inverse agonists to cannabinoid type 1 G-protein coupled receptors (CB1R), and hemopressin fragment NFKF is shown herein to attenuate the symptoms of pilocarpine-induced epileptic seizures. Intracellular peptides EL28 (derived from proteasome 26S protease regulatory subunit 4; Rpt2), PepH (derived from Histone H2B type 1-H), and Pep5 (derived from G1/S-specific cyclin D2) are examples of peptides that function intracellularly. Intracellular peptides are suggested as biological functional molecules, and are also promising prototypes for new drug development.

16 November 2020 in Neuropharmacology
Verified
Journal Article
Closed access
AHAndrea Sterman Heimann
Andrea Sterman Heimann
CDCamila S. Dale
Camila S. Dale
FGFrancisco S. Guimarães
Francisco S. Guimarães
Ricardo Augusto de Melo ReisRicardo Augusto de Melo Reis
Ricardo Augusto de Melo Reis
ANAmi Navon
Ami Navon
EFEmer Ferro
Emer Ferro

1 May 2009 in Physiological Genomics
Verified
Journal Article
Open access
PDF file
SLSilvia Lacchini
Silvia Lacchini
AHAndrea Sterman Heimann
Andrea Sterman Heimann
FEFabiana Evangelista
Fabiana Evangelista
LCLeandro Cardoso
Leandro Cardoso
GSGustavo Justo da Silva
Gustavo Justo da Silva
JKJose Krieger
Jose Krieger
We tested the hypothesis that small changes in angiotensin I-converting enzyme (ACE) expression can alter the vascular response to injury. Male mice containing one, two, three, and four copies of the Ace gene with no detectable vascular abnormality or changes in blood pressure were submitted to cuff-induced femoral artery injury. Femoral thickening was higher in 3- and 4-copy mice (42.4 ± 4.3% and 45.7 ± 6.5%, respectively) compared with 1- and 2-copy mice (8.3 ± 1.3% and 8.5 ± 0.9%, respectively). Femoral ACE levels from control and injured vessels were assessed in 1- and 3-copy Ace mice, which represent the extremes of the observed response. ACE vascular activity was higher in 3- vs. 1-copy Ace mice (2.4-fold, P < 0.05) in the control uninjured vessel. Upon injury, ACE activity significantly increased in both groups [2.41-fold and 2.14-fold ( P < 0.05) for 1- and 3-copy groups, respectively] but reached higher levels in 3- vs. 1-copy Ace mice ( P < 0.05). Pharmacological interventions were then used as a counterproof and to indirectly assess the role of angiotensin II (ANG II) on this response. Interestingly, ACE inhibition (enalapril) and ANG II AT1 receptor blocker (losartan) reduced intima thickening in 3-copy mice to 1-copy mouse values ( P < 0.05) while ANG II treatment significantly increased intima thickening in 1-copy mice to 3-copy mouse levels ( P < 0.05). Together, these data indicate that small physiologically relevant changes in ACE, not associated with basal vascular abnormalities or blood pressure levels, do influence the magnitude of cuff-induced neointima thickening in mice.

1 November 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AHAndrea Sterman Heimann
Andrea Sterman Heimann
AGAchla Gupta
Achla Gupta
IGIvone Gomes
Ivone Gomes
RRRahman Rayees
Rahman Rayees
ASAvner Schlessinger
Avner Schlessinger
LDLakshmi Devi
Lakshmi Devi
The N-terminal region of G protein-coupled receptors can be efficiently targeted for the generation of receptor-selective antibodies. These antibodies are useful for the biochemical characterization of the receptors. In this study, we developed a set of criteria to select the optimal epitope and applied them to generate antibodies to the N-terminal region of 34 different G protein-coupled receptors. The antibody characterization revealed that a subset of antibodies exhibited increased recognition of the receptor following agonist treatment and this increase could be blocked by treatment with the receptor antagonist. An analysis of the epitopes showed that those antibodies that exhibit increased recognition are on average twelve residues long, have an overall net negative charge and are enriched in aspartic and glutamic acids. These antibodies are useful since they facilitate studies examining dose dependent increases in recognition of receptors in heterologous cells as well as in native tissue. Another interesting use of these antibodies is that they facilitate measuring changes in receptor recognition in brain following peripheral drug administration; for example, systemic administration of cocaine, a blocker of dopamine transporter that increases local dopamine levels at the synapse, was found to lead to increases in antibody recognition of dopamine receptors in the brain. Taken together these studies, in addition to describing novel tools to study native receptors, provide a framework for the generation of antibodies to G protein-coupled receptors that can detect ligand-induced conformational changes.

Verified
Journal Article
Open access
PDF file
Renata SilverioRenata Silverio
Renata Silverio
RBRobson Barth
Robson Barth
AHAndrea Sterman Heimann
Andrea Sterman Heimann
PRPatrícia Reckziegel
Patrícia Reckziegel
GSGustavo J Dos Santos
Gustavo J Dos Santos
EFEmer Ferro
Emer Ferro
Peptide DIIADDEPLT (Pep19) has been previously suggested to improve metabolic parameters, without adverse central nervous system effects, in a murine model of diet-induced obesity. Here, we aimed to further evaluate whether Pep19 oral administration has anti-obesogenic effects, in a well-established high-fat diet-induced obesity model. Male Swiss mice, fed either a standard diet (SD) or high-fat diet (HFD), were orally administrated for 30 consecutive days, once a day, with saline vehicle or Pep19 (1 mg/kg). Next, several metabolic, morphological, and behavioral parameters were evaluated. Oral administration of Pep19 attenuated HFD body-weight gain, reduced in approximately 40% the absolute mass of the endocrine pancreas, and improved the relationship between circulating insulin and peripheral insulin sensitivity. Pep19 treatment of HFD-fed mice attenuated liver inflammation, hepatic fat distribution and accumulation, and lowered plasma alanine aminotransferase activity. The inguinal fat depot from the SD group treated with Pep19 showed multilocular brown-fat-like cells and increased mRNA expression of uncoupling protein 1 (UCP1), suggesting browning on inguinal white adipose cells. Morphological analysis of brown adipose tissue (BAT) from HFD mice showed the presence of larger white-like unilocular cells, compared to BAT from SD, Pep19-treated SD or HFD mice. Pep19 treatment produced no alterations in mice behavior. Oral administration of Pep19 ameliorates some metabolic traits altered by diet-induced obesity in a Swiss mice model.

1 June 2025 in Diabetes/Metabolism Research and Reviews
Verified
Journal Article
Open access
AHAndrea Sterman Heimann
Andrea Sterman Heimann
PSPrachi Singh
Prachi Singh
EFEmer S. Ferro
Emer S. Ferro
FGFrank Greenway
Frank Greenway
AKArnon Krongrad
Arnon Krongrad
Background: Conformational‐sensitive antibodies were used to identify the orally active peptide DIIADDEPLT (Pep19) as an inverse agonist of cannabinoid type 1 receptor. Pep19 safely improved metabolic parameters in murine models of diet‐induced obesity, and in healthy dogs. Objectives: To evaluate Pep19's impact on quality of life and body composition in obese adults, hypothesising that the metabolic effects of Pep19 observed in animal models could translate to humans. Methods: Subjects, males ( n = 12) and females ( n = 12), from 46 to 59 years old, weighing 91–106 kg, body mass index between 30 and 35 kg/m 2 , were evaluated over 60 days in a placebo‐controlled, triple‐blinded clinical trial; participants received either a placebo, 2 or 5 mg Pep19 capsules once daily at bedtime. The primary endpoint was a broad measure of quality of life assessed using validated questionnaires. The key secondary endpoints included weight loss, reduction in visceral fat (measured by dual‐energy X‐ray absorptiometry), and changes in waist, hip, and chest measurements. Results: Pep19 was well tolerated with no reported adverse effects. Remarkable reductions in visceral fat were observed in the 5 mg Pep19 group, with a 17 ± 4.7% loss ( p < 0.05), without any change in lean mass. Additionally, sleep quality improved significantly by 35 ± 10% in the 2 mg Pep19 group and 25 ± 16% in the 5 mg Pep19 group ( p < 0.05). In the 5 mg Pep19 group, significant reductions in body weight and waist circumferences were also observed ( p < 0.05). Conclusion: Despite the limitations related to the use of convenience sampling, a small sample size, and a short intervention duration, which may restrict generalisation and health claims, Pep19 demonstrates exceptional innovative potential as a novel approach to reduce visceral fat and improve sleep quality.